Stockreport

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts [Seeking Alpha]

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806
PDF ABUS's valuation is driven by its hepatitis B pipeline, especially imdusiran, with clinical milestones outweighing speculative legal outcomes. Recent financials show [Read more]